Cart (0)
Ridany I et. al. (December 2023). Aromatic Hydrocarbon Receptor Repressor (AHRR) Is a Biomarker of Ambient Air Pollution Exposure and Coronary Artery Disease (CAD) Environ Toxicol Pharmacol. :104344.
In a study with 220 subjects, AHRR methylation (cg05575921) was significantly lower in ever smokers compared to never smokers. Higher urinary levels of specific aromatic hydrocarbons were associated with AHRR hypomethylation, independent of smoking. AHRR hypomethylation was significantly linked to obstructive coronary artery disease (CAD), suggesting its potential as a biomarker for the association between ambient air pollution and CAD, pending further validation.
Products Used: Methylamp DNA Modification Kit
Zhan Y et. al. (December 2023). Maternal exposure to E 551 during pregnancy leads to genome-wide DNA methylation changes and metabolic disorders in the livers of pregnant mice and their fetuses J Hazard Mater. 465:133233.
This study explores the effects of prenatal exposure to silica nanoparticles (E 551) on maternal and fetal health. High-dose exposure leads to fetal resorption and hepatic inflammation in both maternal and fetal livers. Epigenetic analysis reveals significant global DNA methylation changes, suggesting a potential risk of metabolic disorders. Impaired glucose tolerance and altered expression of metabolism-related genes and proteins further support these findings, emphasizing the importance of considering epigenetic factors in assessing the toxicity of maternal exposure to food-grade nanomaterials during pregnancy.
Products Used: MethylFlash Global DNA Methylation (5-mC) ELISA Easy Kit (Colorimetric)
Ishimota M et. al. (December 2023). Chemical tolerance related to the ABC transporter gene and DNA methylation in cladocera (Daphnia magna) Environ Toxicol.
In this study on Daphnia magna, multigenerational exposure to the carbamate insecticide pirimicarb revealed increased chemical tolerance. Across 15 generations, ABC transporter gene (ABCt) mRNA levels showed a positive relationship with altered pirimicarb sensitivity, indicating ABCt's association with chemical tolerance. Moreover, exposure to the demethylating agent 5-azacytidine reduced DNA methylation levels in pirimicarb-tolerant clones, highlighting the contribution of DNA methylation to chemical tolerance.
Products Used: MethylFlash Global DNA Methylation (5-mC) ELISA Easy Kit (Colorimetric)
Geng H et. al. (December 2023). Cadmium-induced global DNA hypermethylation promoting mitochondrial dynamics dysregulation in hippocampal neurons Geng H et. al. (December 2023).
The article explores the impact of 5 μM cadmium on cultured hippocampal neurons. Cadmium induces neurotoxic effects, causing structural degradation, reduced viability, and altered mitochondrial dynamics, including morphology changes and decreased ATP production. Cadmium exposure increases global DNA methylation and upregulates DNMT1 and DNMT3α expression. Treatment with 5-Aza-CdR mitigates these effects, suggesting a role for genome methylation in cadmium-induced neurotoxicity.
Products Used: MethylFlash Methylated DNA 5-mC Quantification Kit (Colorimetric)
Lizárraga D et. al. (December 2023). Global DNA methylation and miR-126-3p expression in Mexican women with gestational diabetes mellitus: a pilot study Mol Biol Rep. 51(1):5.
The study explores global DNA methylation and miR-126-3p expression in Mexican women with gestational diabetes mellitus (GDM). In GDM patients, placenta samples show increased 5-methylcytosine, while plasma samples exhibit decreased levels. Conversely, miR-126-3p expression is higher in GDM plasma. DNA methylation correlates with glucose levels in placenta and plasma, while miR-126-3p expression correlates with plasma glucose and maternal BMI. These findings suggest potential diagnostic and preventive approaches for GDM.
Products Used: MethylFlash Methylated DNA Quantification Kit (Fluorometric)
Zhang M et. al. (December 2023). DNA methylation regulates RNA m6 A modification through transcription factor SP1 during the development of porcine somatic cell nuclear transfer embryos Cell Prolif. :e13581.
This study investigates the role of RNA N6-methyladenosine (m6A) in porcine somatic cell nuclear transfer (SCNT) embryo development using bone marrow mesenchymal stem cells (pBMSCs) and embryonic fibroblasts (pEFs). Higher RNA m6A levels in pBMSCs enhance SCNT embryo development. DNA methylation influences METTL14 expression via the SP1 transcription factor, impacting RNA m6A levels and improving SCNT embryo development when modulated in donor cells. METTL14 overexpression enhances RNA m6A levels, benefiting SCNT embryo development, while knockdown has the opposite effect. This study highlights the interplay between RNA m6A and DNA methylation in SCNT embryo development.
Products Used: EpiQuik m6A RNA Methylation Quantification Kit (Colorimetric)
Zheng X et. al. (December 2023). Transcriptome-wide N6-methyladenosine methylation profile of atherosclerosis in mice BMC Genomics. 24(1):774.
The article explores the transcriptome-wide distribution of N6-methyladenosine (m6A) modification in AS and its underlying mechanism. Global m6A levels and methyltransferase METTL3 increase in AS mice, while demethylase ALKBH5 decreases. MeRIP-seq reveals m6A methylation maps associated with AS-related pathways. Integrated analysis shows a negative correlation between m6A methylation abundance and gene expression, highlighting the potential AS biomarker Fabp5. This study sheds light on the role of m6A modification in AS.
Products Used: EpiQuik m6A RNA Methylation Quantification Kit (Colorimetric)
Li L et. al. (December 2023). ALKBH5 regulates ovarian cancer growth via demethylating long noncoding RNA PVT1 in ovarian cancer J Cell Mol Med.
This study investigates the impact of N6-methyladenosine (m6A) modification on PVT1 in OV. ALKBH5, responsible for PVT1 demethylation, is upregulated in OV tissues. ALKBH5 binds to and stabilizes PVT1, influencing FOXM1 levels. ALKBH5 knockdown suppresses OV growth, invasion, and enhances chemotherapy sensitivity by regulating the PVT1/FOXM1 axis. These findings highlight ALKBH5's role in OV malignancy through m6A modification of PVT1.
Products Used: EpiQuik m6A RNA Methylation Quantification Kit (Colorimetric)
Zhou Y et. al. (December 2023). Celastrol suppresses human pancreatic cancer via m6A-YTHDF3-mediated downregulation of Claspin and Bcl-2 Discov Oncol. 14(1):233.
The study identifies Bcl-2 and Claspin as key targets of celastrol. Mechanistically, celastrol downregulates METTL3, reducing m6A levels in Claspin and Bcl-2 mRNA, leading to their degradation. Notably, celastrol achieves this effect through an m6A-YTHDF3-mediated pathway. This research unveils a novel mechanism for celastrol in inhibiting pancreatic cancer progression.
Products Used: EpiQuik m6A RNA Methylation Quantification Kit (Colorimetric)
Yin X et. al. (December 2023). m6A-modified RIPK4 facilitates proliferation and cisplatin resistance in epithelial ovarian cancer Gynecol Oncol. 180:99-110.
The article explores the role of N6-methyladenosine (m6A) modification in this process. The research identifies Receptor-Interacting Serine/Threonine-Protein Kinase 4 (RIPK4) as an oncogene in EOC, promoting tumor proliferation and cisplatin resistance. The m6A methyltransferase METTL3 facilitates m6A modification, while YTHDF1 prevents RNA degradation, leading to increased RIPK4 expression. This mechanism activates NF-κB, contributing to tumor growth and cisplatin resistance. The study uncovers a novel pathway involving m6A-modified RIPK4 in EOC chemoresistance.
Products Used: EpiQuik m6A RNA Methylation Quantification Kit (Colorimetric)
Zhang G et. al. (December 2023). Targeting AKT induced Ferroptosis through FTO/YTHDF2-dependent GPX4 m6A methylation up-regulating and degradating in colorectal cancer Cell Death Discov. 9(1):457.
This study reveals that downregulation of demethylase FTO during AKT targeting increases m6A methylation of GPX4, facilitating its degradation by YTHDF2. The identified methylated site (193) undergoes FTO-mediated demethylation and YTHDF2 recognition. AKT inhibition elevates ROS levels, negatively regulating GPX4 expression. Protective autophagy is triggered by MK2206, and its inhibition enhances ferroptosis, intensifying MK2206's anti-tumor efficacy. This uncovers the FTO/YTHDF2/GPX4 axis as a potential therapeutic target for CRC.
Products Used: EpiQuik CUT&RUN m6A RNA Enrichment (MeRIP) Kit
Zheng R et. al. (December 2023). Neuromedin U regulates the anti-tumor activity of CD8+ T cells and glycolysis of tumor cells in the tumor microenvironment of pancreatic ductal adenocarcinoma in an NMUR1-dependent manner Cancer Sci.
The article investigates Neuromedin U (NMU) in pancreatic ductal adenocarcinoma (PDAC). NMU, upregulated in PDAC patients, correlates with poor prognosis. Nmu gene knockout enhances anti-tumor functions of CD8+ T cells via NMU receptor 1. NMU promotes glycolytic metabolism in PDAC tumors, affecting lactate production regulators. LDHA inhibitor reduces NMU-stimulated lactic acid production, enhancing CD8+ T cell anti-tumor activity. NMU's impact on glycolysis involves the PI3K/AKT pathway, suggesting NMU as a potential PDAC therapy target.
Products Used: NMUR1 Polyclonal Antibody
Tanaka M et. al. (December 2023). Blockade of angiotensin II modulates insulin-like growth factor 1-mediated skeletal muscle homeostasis in experimental steatohepatitis Biochim Biophys Acta Mol Cell Res. 1871(2):119649.
The study investigates the impact of combining the angiotensin II receptor blocker (ARB) losartan and insulin-like growth factor 1 (IGF-1) on skeletal muscle atrophy in a steatohepatitis mouse model. ARB or IGF-1 treatments individually mitigate muscle atrophy induced by steatohepatitis. However, the combined therapy shows enhanced efficacy, suppressing protein degradation and inflammation. ARB also increases hepatic and plasma IGF-1 levels, improving steatohepatitis and promoting skeletal muscle protein synthesis. The study suggests this combined therapy as a potential treatment for nonalcoholic steatohepatitis-induced skeletal muscle wasting.
Products Used: EpiQuik Nuclear Extraction Kit
Berkholz J et. al. (December 2023). Smyd1: Implications for novel approaches in rhabdomyosarcoma therapy Exp Cell Res. 434(2):113863.
The study explores Smyd1 and skNAC in rhabdomyosarcoma (RMS), a common childhood soft-tissue sarcoma. Smyd1 overexpression enhances RMS cell differentiation and reduces proliferation and metastasis. The research suggests potential therapeutic strategies targeting Smyd1 activity, focusing on sumoylation, H3K4me2/3 marks, and calpain activity. This offers a promising avenue for novel RMS therapies.
Products Used: EpiQuik Total Histone Extraction Kit
Wu SY et. al. (December 2023). IDR-targeting compounds suppress HPV genome replication via disruption of phospho-BRD4 association with DNA damage response factors Mol Cell.
In this study, researchers identified small molecules targeting a phosphorylated intrinsically disordered region (IDR) of BRD4. These compounds disrupt the association of phospho-BRD4 (pBRD4) with DNA damage response factors, 53BP1 and BARD1, crucial for human papillomavirus (HPV) genome replication in keratinocytes. The discovery highlights the potential of these compounds as antiviral agents and offers insights into the role of epigenetic regulation in virus-host interactions and cancer development.
Products Used: Histone Acetyl H4ac Peptide Biotinylated
